By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


SAGE Therapeutics 

29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: n/a Fax: n/a



Start Up

Company News
SAGE Therapeutics To Participate In The 2014 Leerink Partners Rare Disease Roundtable 9/25/2014 7:42:13 AM
SAGE Therapeutics Appoints Michael F. Cola To The Company's Board Of Directors 9/16/2014 12:51:30 PM
SAGE Therapeutics Presents New Preclinical Data On SAGE-217 At Eilat Conference On New Anti-Epileptic Drugs 9/2/2014 1:47:41 PM
SAGE Therapeutics Reports Second Quarter 2014 Financial Results 8/14/2014 8:09:08 AM
SAGE Therapeutics To Present At Canaccord Genuity 34th Annual Growth Conference 8/7/2014 10:46:26 AM
Ligand Pharmaceuticals Inc. (LGND) Partner SAGE Therapeutics Receives Fast Track Designation For Captisol-enabled SAGE-547 To Treat Status Epilepticus 7/23/2014 12:24:03 PM
SAGE Therapeutics Announces Closing Of Initial Public Offering 7/23/2014 12:16:23 PM
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014 6:49:33 AM
SAGE Therapeutics Announces Full Exercise Of Over-Allotment Option 7/21/2014 4:04:07 PM
SAGE Therapeutics Announces Pricing Of Initial Public Offering 7/18/2014 10:58:40 AM